Patent · US Active

TLR7/8 antagonists and uses thereof

US11629134B2 · kind B2 · utility

0Cited by
15References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 19, 2020
Grant dateApr 18, 2023
Priority date—
Expiry dateDec 19, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.